Here is an analytical blog comparing the IQVIA MFR Dec 2025 report with the previously reviewed PharmaTrac Dec 2025 report:
1. Market Size and Growth: Broad Alignment
Both reports confirm that the IPM is growing steadily, though with slightly different numbers:
- PharmaTrac: Estimates IPM at ₹2.40 lakh crores with 8.2% MAT growth (realistic scenario).
- IQVIA: Reports IPM at ₹2.50 lakh crores with 8.9% MAT growth.
The difference (~₹10,000 Cr) likely stems from data sources, sample coverage, and projection models. Both, however, signal a post-pandemic stabilization, with chronic therapies outpacing acute ones.





